In-Depth Review of Segments, Industry Developments, and Key Competitors in the Viral Hepatitis Market

The viral hepatitis market is on a steady upward trajectory, driven by growing global efforts to combat the disease and advancements in medical technology. Increasing investments in innovative treatments and expanded diagnostic methods are setting the stage for consistent growth through 2030. Below is an overview of the market's projected size, key players, emerging trends, and segmentation details.

Projected Expansion and Market Value of the Viral Hepatitis Market
The viral hepatitis market is anticipated to reach a value of $20.85 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.7%. This expansion is propelled by intensified hepatitis eradication campaigns, rising investment in new antiviral medications, broader availability of point-of-care testing, increased use of combination drug therapies, and a surge in global screening initiatives. Key trends shaping the market include greater acceptance of cutting-edge antiviral treatments, more widespread use of molecular diagnostic tools, heightened emphasis on early disease identification, expanded immunization efforts, and improved management of chronic hepatitis cases.

Download a free report of the viral hepatitis market report:
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Top Companies Leading the Viral Hepatitis Industry
The viral hepatitis sector features several prominent pharmaceutical and biotechnology firms such as Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., and Wockhardt Ltd.

Significant Acquisition Enhancing Market Position
In November 2023, the UK-based company GSK plc secured exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals in a $1 billion deal. This acquisition includes JNJ-3989, also known as ARO-HBV, an antisense oligonucleotide drug aimed at treating chronic hepatitis B. By adding this promising therapy to its portfolio, GSK plans to strengthen its foothold in the hepatitis treatment landscape. Janssen Pharmaceuticals, a Belgian subsidiary of Johnson & Johnson, is well-regarded for its work on infectious disease treatments, including chronic hepatitis B.

View the full viral hepatitis market report:
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Current Trends Shaping the Viral Hepatitis Market
Leading firms are increasingly adopting advanced immunoassay technologies, such as automated dual-marker immunoassays, to improve early detection and ongoing monitoring of hepatitis infections. These tests simultaneously identify both antigens and antibodies from a single sample, offering near-real-time infection status, reducing diagnostic windows, and enhancing screening efficiency.

A notable example is Roche Diagnostics India's launch in July 2023 of the Elecsys HCV Duo test. This dual antigen-antibody immunoassay detects hepatitis C virus by independently identifying HCV core antigen and anti-HCV antibodies from one serum or plasma sample. Compatible with automated analyzers like cobas e 402 and e 801, the Elecsys HCV Duo allows for earlier diagnosis of active HCV infections, quicker patient care linkage, streamlined workflows, and less strain on healare systems.

Detailed Segmentation of the Global Viral Hepatitis Market
This report breaks down the viral hepatitis market into key categories:
1) Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) Diagnosis Method: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnostic Techniques
3) Treatment Type: Antiviral Drugs, Surgery, Vaccines, Immune Modulator Drugs, Other Treatments
4) Administration Routes: Oral, Parenteral, Other Methods
5) End Users: Hospitals, Specialty Clinics, Homecare Settings, Other Users

Further subcategories include:
- Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A
- Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier
- Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C
- Other Disease Types: Hepatitis D, Hepatitis E

This comprehensive segmentation provides a thorough understanding of the viral hepatitis market landscape and its varied facets.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.